Viatris Work in process decreased by 13.6% to $424.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.0%, from $493.70M to $424.80M. Over 5 years (FY 2020 to FY 2025), Work in process shows a downward trend with a -19.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.15B | $836.40M | $993.30M | $767.50M | $821.70M | $824.60M | $755.40M | $697.40M | $1.13B | $1.03B | $602.10M | $1.10B | $576.50M | $554.80M | $527.30M | $493.70M | $531.70M | $516.00M | $491.70M | $424.80M |
| QoQ Change | — | -27.2% | +18.8% | -22.7% | +7.1% | +0.4% | -8.4% | -7.7% | +62.3% | -8.9% | -41.6% | +82.3% | -47.5% | -3.8% | -5.0% | -6.4% | +7.7% | -3.0% | -4.7% | -13.6% |
| YoY Change | — | — | — | — | -28.5% | -1.4% | -24.0% | -9.1% | +37.8% | +25.0% | -20.3% | +57.4% | -49.1% | -46.2% | -12.4% | -55.0% | -7.8% | -7.0% | -6.8% | -14.0% |
| % of Inventories | 25.6% | 20.5% | 25.0% | 20.2% | 22.7% | 24.4% | 21.5% | 19.0% | 31.1% | 28.1% | 17.4% | 28.7% | 14.6% | 13.6% | 13.7% | 12.1% | 12.5% | 12.6% | 12.3% | 10.8% |
| Share Change | — | -5.1pp | +4.5pp | -4.8pp | +2.5pp | +1.6pp | -2.9pp | -2.4pp | +12.1pp | -3.0pp | -10.7pp | +11.4pp | -14.1pp | -1.0pp | +0.1pp | -1.6pp | +0.4pp | +0.1pp | -0.3pp | -1.5pp |